- $22.67m
- $122.25m
- $29.62m
- 44
- 58
- 41
- 45
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.22 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -146.23% | ||
| Return on Equity | n/a | ||
| Operating Margin | -130.55% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 176.32 | 235.31 | 140.73 | 46.8 | 29.62 | 9.98 | 9.6 | -35.07% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
FibroGen, Inc. is a biopharmaceutical company focused on the development of novel therapies at the frontiers of cancer biology and anemia. It is developing FG-3246, a potential first-in-class antibody-drug conjugate (ADC) targeting CD46, for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and potentially other cancers. This program also includes the development of FG-3180, an associated CD46-targeted positron emission tomography (PET) biomarker and imaging agent. It is also developing Roxadustat, an oral medication, first-in-class, oral small molecule hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), which is evaluated for the treatment of anemia in patients with chronic kidney disease (CKD), anemia associated with myelodysplastic syndromes and chemotherapy-induced anemia. Roxadustat is approved in China, Europe, Japan, and numerous other countries for the treatment of anemia of CKD in adult patients on dialysis (DD) and not on dialysis (NDD).
Directors
- James Schoeneck CHM (63)
- Enrique Conterno CEO (54)
- Juan Graham CFO (46)
- Christine Chung SVP (53)
- Elias Kouchakji SVP (65)
- John Hunter CSO (56)
- Mark Eisner OTH (55)
- Thane Wettig OTH (56)
- Thomas Kearns LED (84)
- Suzanne Blaug IND (62)
- Aoife Brennan IND (45)
- Benjamin Cravatt IND
- Jeffrey Edwards IND (61)
- Jeffrey Henderson IND (56)
- Maykin Ho IND (68)
- Gerald Lema IND (60)
- Rory Riggs IND (68)
- Last Annual
- December 31st, 2024
- Last Interim
- March 31st, 2025
- Incorporated
- September 29th, 1993
- Public Since
- November 14th, 2014
- No. of Shareholders
- 93
- No. of Employees
- 225
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Global Select Market- Shares in Issue
- 4,041,759
- Address
- 350 BAY STREET, SUITE 100 #6009, SAN FRANCISCO, 94133
- Web
- https://www.fibrogen.com/
- Phone
- +1 4159781200
- Auditors
- PricewaterhouseCoopers LLP
Upcoming Events for FGEN
Q3 2025 FibroGen Inc Earnings Release
Similar to FGEN
4D Molecular Therapeutics
NASDAQ Global Select Market
Aardvark Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
Acadia Pharmaceuticals
NASDAQ Global Select Market
FAQ
What is the Fibrogen share price?
As of Today at 20:36 UTC, shares in Fibrogen are trading at $5.61. This share price information is delayed by 15 minutes.
How has the Fibrogen share price performed this year?
Shares in Fibrogen last closed at $5.61 and the price had moved by -67.53% over the past 365 days. In terms of relative price strength the Fibrogen share price has underperformed the S&P500 Index by -70.97% over the past year.
What are the analyst and broker recommendations for Fibrogen?
The overall consensus recommendation for Fibrogen is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Fibrogen dividend yield?
Fibrogen does not currently pay a dividend.
Does Fibrogen pay a dividend?
Fibrogen does not currently pay a dividend.
When does Fibrogen next pay dividends?
Fibrogen does not currently pay a dividend.
How do I buy Fibrogen shares?
To buy shares in Fibrogen you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Fibrogen?
As of the previous close price of $5.61, shares in Fibrogen had a market capitalisation of $22.67m.
Where are Fibrogen shares listed?
Here are the trading details for Fibrogen:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: FGEN
What kind of share is Fibrogen?
Based on an overall assessment of its quality, value and momentum Fibrogen is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Fibrogen share price forecast for 2025?
The analyst consensus target price for shares in Fibrogen is $250.00. That is 4356.33% above the last closing price of $5.61.
Analysts covering Fibrogen currently have a consensus Earnings Per Share (EPS) forecast of -$12.13 for the next financial year.
Find out moreWhat is the trend in the Fibrogen share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Fibrogen. Over the past six months, its share price has underperformed the S&P500 Index by -60.55%.
As of the last closing price of $5.61, shares in Fibrogen were trading -40.76% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Fibrogen PE Ratio?
The Fibrogen PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $5.61.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Fibrogen?
Fibrogen's management team is headed by:
- James Schoeneck - CHM
- Enrique Conterno - CEO
- Juan Graham - CFO
- Christine Chung - SVP
- Elias Kouchakji - SVP
- John Hunter - CSO
- Mark Eisner - OTH
- Thane Wettig - OTH
- Thomas Kearns - LED
- Suzanne Blaug - IND
- Aoife Brennan - IND
- Benjamin Cravatt - IND
- Jeffrey Edwards - IND
- Jeffrey Henderson - IND
- Maykin Ho - IND
- Gerald Lema - IND
- Rory Riggs - IND